LAX1 Polyclonal antibody

LAX1 Polyclonal Antibody for WB, IF, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IF, IHC, ELISA

Conjugate

Unconjugated

Cat no : 21557-1-AP

Synonyms

LAX, LAX1



Tested Applications

Positive WB detected inHeLa cells, Jurkat cells
Positive IHC detected inhuman spleen tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHeLa cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:20-1:200
Immunofluorescence (IF)IF : 1:20-1:200
Sample-dependent, check data in validation data gallery

Published Applications

WBSee 2 publications below

Product Information

The immunogen of 21557-1-AP is LAX1 Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse, rat
Cited Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen LAX1 fusion protein Ag15599 相同性解析による交差性が予測される生物種
Full Name lymphocyte transmembrane adaptor 1
Calculated molecular weight 398 aa, 44 kDa
Observed molecular weight 44 kDa
GenBank accession numberBC069650
Gene symbol LAX1
Gene ID (NCBI) 54900
RRIDAB_10732821
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Protocols

Product Specific Protocols
WB protocol for LAX1 antibody 21557-1-APDownload protocol
IHC protocol for LAX1 antibody 21557-1-APDownload protocol
IF protocol for LAX1 antibody 21557-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
mouseWB

J Immunol

Mettl14-Mediated m6A Modification Is Essential for Germinal Center B Cell Response.

Authors - Hengjun Huang
humanWB

Cell Rep Med

A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma

Authors - Francesco Di Meo